title: [Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function].
abstract: OBJECTIVE
  To examine effectiveness and safety of quadropril.
  
  
  METHODS
  Changes in blood pressure (BP), heart rate (HR), levels of glucose, potassium and creatinine, creatinine clearance were studied in 120 patients (48 males and 72 females, mean age 60.6 +/- 0.7 years) with mild to moderate arterial hypertension (AH) with average duration 13.8 +/- 0.7 years. The patients were divided into 3 groups: with AH (n = 40), AH + noninsulindependent diabetes mellitus (DM) (n = 43), AH and nephropathy (n = 37). 8-week treatment was performed with a standard dose of 6 mg/day (1 tablet of quadropril). Control examinations were made 2, 4 and 8 weeks after the treatment.
  
  
  RESULTS
  After 8 weeks of treatment a decrease in systolic blood pressure in AH group was 24.0 +/- 3.0 mm Hg and in diastolic blood pressure 16.3 +/- 1.3 mm Hg (P < 0.001). In the group with DM this decrease was 22.4 +/- 2.8 mm Hg and 15.7 +/- 1.4 mm Hg (p < 0.001), respectively. In the group with nephropathy this decrease was 26.4 +/- 2.4 and 16.5 +/- 1.3 mm Hg (p < 0.001), respectively. Heart rate changed significantly only in diabetics: from 75.1 +/- 1.7 to 72.9 +/- 1.3 beats/min. Biochemical parameters in the hypertensive and diabetic patients did not change significantly. In the nephropathy group there was a significant decrease in creatinine and increase in creatinine clearance. Their level of glucose and potassium changed insignificantly.
  
  
  CONCLUSIONS
  The treatment with quadropril results in a significant decrease in blood pressure, does not influence parameters of carbohydrate metabolism, improves nitrogen eliminating function of the kidneys.
authors.forename: V V
authors.initials: VV
authors.lastname: Iakusevich
authors.forename: M E
authors.initials: ME
authors.lastname: Mozheĭko
authors.forename: Sh Kh
authors.initials: ShKh
authors.lastname: Paliutin
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Berezina
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Martsevich
authors.forename: S A
authors.initials: SA
authors.lastname: Shal'nova
authors.forename: A D
authors.initials: AD
authors.lastname: Deev
authors.forename: N P
authors.initials: NP
authors.lastname: Kutishenko
authors.forename: E V
authors.initials: EV
authors.lastname: Alimova
authors.forename: I P
authors.initials: IP
authors.lastname: Koniakhina
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Semenova
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood / Q000652:urine; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D004656:Enalapril / Q000008:administration & dosage* / Q000031:analogs & derivatives; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004656:Enalapril; C052555:spirapril; D003404:Creatinine
vernacular_title: Spirapril - novyĭ ingibitor angiotenzinprevrashchaiushchego fermenta dlitel'nogo deĭstviia: éffektivnost' i bezopasnost' u bol'nykh arterial'noĭ gipertonieĭ v sochetanii s sakharnym diabetom i narushennoĭ funktsieĭ pochek.